4basebio UK
Societas
("4basebio", the "Company" or the
“Group”)
Admission to
Trading on AIM and First Day of Dealings
4basebio UK Societas (AIM: 4BB), the specialist life sciences
group focused on exploiting its intellectual property in the field
of gene therapies and DNA vaccines, is pleased to announce the
admission of its ordinary shares to trading on the AIM market of
the London Stock Exchange. Dealings will commence at 8.00 a.m. today, Wednesday 17 February 2021, under the ticker 4BB
(ISIN GB00BLD8ZL39).
Upon Admission, the Company will have 12,317,473 ordinary
shares in issue and a market capitalisation of approximately £14.5
million.
Heikki
Lanckriet, Chief Executive Officer of 4basebio,
commented:
“We are delighted to be admitted to
AIM today. As a Cambridge based company with significant ambitions,
we believe AIM is the ideal market to support our further
development. We would also like to extend our thanks to our staff,
advisors and shareholders who continue to support our ongoing
growth strategy.”
Cairn Financial Advisers LLP is acting as Nominated Adviser to
the Company and finnCap is acting as Broker.
Company Highlights
4basebio is a specialist life sciences group focused on
therapeutic DNA for gene therapies and DNA vaccines and providing
solutions for effective and safe delivery of these DNA based
products to patients. It is the intention of the Company to become
a market leader in the manufacture and supply of high purity,
synthetic DNA for research, therapeutic and pharmacological use.
The immediate objectives of 4bb are to validate and scale its DNA
synthesis and advance its collaborations to facilitate the
functional validation of its DNA based products and gene delivery
solutions.
The Company divested from 4basebio AG (“4bb AG”), a German
company listed on the Prime Standard segment of the Frankfurt Stock
Exchange, following the disposal by 4bb AG (then named Expedeon AG)
of its proteomics and immunology business to AIM-quoted Abcam plc
in January 2020 for €120million.
Following the disposal, 4bb AG retained its genomics business which
owned and licensed certain intellectual property including its
proprietary, patent-protected technology, TruePrime™. This is the
foundation for building the Company’s synthetic DNA manufacturing
business which 4bb AG transferred to the Company along with funding
to continue the Company’s development and investment.
On Admission, the Company will have cash reserves of
approximately £14.4million which the Directors consider will
provide sufficient working capital for the development and scale-up
of the business to commercialisation.
The Company has a wholly-owned Spanish subsidiary, 4basebio
S.L.U. (“4bb Spain”) and a wholly-owned UK subsidiary, 4basebio UK
Limited (“4bb UK”) which in turn wholly-owns 4basebio Discovery
Limited (“4bb Discovery”).
4bb UK focuses on the DNA validation and scaling work required
as a prerequisite to developing Good Manufacturing Practice (“GMP”)
grade DNA, suitable for use in gene therapies and DNA vaccines. It
is expected that 4bb UK’s operations will continue to expand as it
becomes the Group’s centre of large-scale production.
4bb Discovery was created as a particle and indication research
and development arm of the Group with the intention of developing
intellectual property around non-viral delivery platforms.
4bb Spain undertakes primary
DNA synthesis research and is involved in the manufacture of
enzymes used in the DNA manufacturing process as well as in other
diagnostic and research applications.
The Admission Document can be found on 4basebio’s
website: www.4basebio.com
For further enquiries, please
contact:
4basebio UK
Societas
Heikki Lanckriet |
+44 (0)12 2396
7943 |
|
|
Nominated
Adviser
Cairn Financial Advisers LLP
Jo Tuner / Sandy Jamieson |
+44 (0)20 7213
0880
|
|
|
Broker
finnCap Ltd
Geoff Nash
Richard Chambers/Charlotte Sutcliffe |
+44 (0)20 7220
0500 |
Caution regarding forward looking
statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi?ed by their use of terms and phrases such as ''believe'',
''could'', "should" ''envisage'', ''estimate'', ''intend'',
''may'', ''plan'', ''potentially'', "expect", ''will'' or the
negative of those, variations or comparable expressions, including
references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other
expenditures (including the amount, nature and sources of funding
thereof), competitive advantages, business prospects and
opportunities. Such forward looking statements re?ect the
Directors' current beliefs and assumptions and are based on
information currently available to the Directors.